
Endre Zima

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/63451/publications.pdf Version: 2024-02-01



ENIDE 71MA

#	Article	IF	CITATIONS
1	Lateral left ventricular lead position is superior to posterior position in longâ€ŧerm outcome of patients who underwent cardiac resynchronization therapy. ESC Heart Failure, 2020, 7, 3374-3382.	1.4	14
2	The role of age in post-cardiac arrest therapy in an elderly patient population. Physiology International, 2020, 107, 319-336.	0.8	6
3	Long-term single-centre large volume experience with transseptal endocardial left ventricular lead implantation. Europace, 2019, 21, 1237-1245.	0.7	11
4	Vitamin D Deficiency Predicts Poor Clinical Outcomes in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy. Disease Markers, 2019, 2019, 1-7.	0.6	8
5	Quality of life measured with EuroQol-five dimensions questionnaire predicts long-term mortality, response, and reverse remodelling in cardiac resynchronization therapy patients. Europace, 2018, 20, 1506-1512.	0.7	9
6	De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis. Heart Failure Reviews, 2018, 23, 15-26.	1.7	32
7	Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. Europace, 2017, 19, euw193.	0.7	17
8	Minimal Invasive Left Ventricular Lead Repositioning is Safe and Effective in Distal Left Ventricular Lead Positions. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 488-493.	0.5	1
9	Oxidative Stress-Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-12.	1.9	24
10	Complement C3a predicts outcome in cardiac resynchronization therapy of heart failure. Inflammation Research, 2016, 65, 933-940.	1.6	7
11	Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients. Europace, 2016, 18, 550-559.	0.7	17
12	The ratio of the neutrophil leucocytes to the lymphocytes predicts the outcome after cardiac resynchronization therapy. Europace, 2016, 18, 747-754.	0.7	20
13	Radiofrequency ablation of focal atrial tachycardia: Benefit of electroanatomical mapping over conventional mapping. Acta Physiologica Hungarica, 2015, 102, 252-262.	0.9	6
14	Comparison of the Effects of Epicardial and Endocardial Cardiac Resynchronization Therapy on Transmural Dispersion of Repolarization. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1099-1105.	0.5	11
15	Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy withÂpacemaker on mortality in heart failure patients: results of a highâ€volume, singleâ€centre experience. European Journal of Heart Failure, 2014, 16, 1323-1330.	2.9	55
16	Direct comparison of steroid and non-steroid eluting small surface pacing leads: Randomized, multicenter clinical trial. Cardiology Journal, 2013, 20, 431-438.	0.5	7
17	Usefulness of electroanatomical mapping during transseptal endocardial left ventricular lead implantation. Europace, 2012, 14, 599-604.	0.7	16
18	Long-term experience with coronary sinus side branch stenting to stabilize left ventricular electrode position. Heart Rhythm, 2011, 8, 845-850.	0.3	28

Endre Zima

#	Article	IF	CITATIONS
19	Minimal invasive coronary sinus lead reposition technique for the treatment of phrenic nerve stimulation. Europace, 2008, 10, 1157-1160.	0.7	17
20	Stabilization of the Coronary Sinus Electrode Position with Coronary Stent Implantation to Prevent and Treat Dislocation. Journal of Cardiovascular Electrophysiology, 2007, 18, 303-307.	0.8	45
21	The Effect of Induction Method on Defibrillation Threshold and Ventricular Fibrillation Cycle Length. Journal of Cardiovascular Electrophysiology, 2006, 17, 377-381.	0.8	19
22	Changes of Endothelin-1 and Big Endothelin-1 Levels and Action Potential Duration during Myocardial Ischemia-reperfusion in Dogs with and without Ventricular Fibrillation. Journal of Cardiovascular Pharmacology, 2004, 44, S376-S379.	0.8	13
23	Shortening the Second Phase Duration of Biphasic Shocks: Effects of Class III Antiarrhythmic Drugs on Defibrillation Efficacy in Humans. Journal of Cardiovascular Electrophysiology, 2001, 12, 824-827.	0.8	10
24	Arrhythmogenic action of endothelin-1. Cardiovascular Research, 2000, 48, 357-358.	1.8	2